Lead Sponsor

AbbVie

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

•Main Observational Study:
•1. Able and willing to provide written consent
•2. Previously enrolled in a clinical study of RGX-314 and received a single subretinal administration of RGX-314
•Exclusions Criteria:
•1\. None
•Fellow Eye Substudy:
•1. Age ≤ 93 years
•2. Currently or previously enrolled in the main observational study
•3. Diagnosis of bilateral choroidal neovascularization secondary to age-related macular degeneration
•4. Active nAMD in the fellow eye
•5. BCVA between ≤ 80 and ≥ 20 letters in the fellow eye

•1. CNV or macular edema in the fellow eye secondary to causes other than nAMD
•2. Subfoveal fibrosis or atrophy in the fellow eye
•3. Advanced glaucoma or history of secondary glaucoma in the fellow eye or any invasive procedure to treat glaucoma
•4. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months
•5. History of intraocular surgery in the fellow eye within 12 weeks of screening
•6. History of intravitreal therapy, such as intravitreal steroid injection or investigational product, other than an intravitreal therapy for nAMD, in the fellow eye within 6 months of screening

Related studies

NCT07440225 · Macular Degeneration, Age-Related Macular Degeneration, and more

NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)

NCT06439576 · Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, and more

NCT05562947 · Neovascular Age-related Macular Degeneration, nAMD

NCT05904028 · Neovascular Age-related Macular Degeneration

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy